Published in Eur Respir J on April 12, 2006
Chronic thromboembolic pulmonary hypertension. Neth Heart J (2014) 1.18
Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag (2007) 1.09
How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol (2006) 1.03
Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline. Can Respir J (2010) 0.92
Pulmonary hypertension in Portugal: first data from a nationwide registry. Biomed Res Int (2013) 0.90
Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension. PLoS One (2012) 0.87
Chronic thromboembolic pulmonary hypertension (CTEPH). Heart (2007) 0.87
Standard PAH therapy improves long term survival in CTEPH patients. Clin Res Cardiol (2010) 0.84
Pulmonary hypertension in Saudi Arabia: A single center experience. Ann Thorac Med (2013) 0.84
Clinical worsening during long-term follow-up in inoperable chronic thromboembolic pulmonary hypertension. Lung (2011) 0.79
Chronic thromboembolic pulmonary hypertension. Curr Treat Options Cardiovasc Med (2010) 0.78
Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism. Neth Heart J (2009) 0.76
Long-term efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension. Neth Heart J (2009) 0.76
Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension. Thorax (2007) 0.76
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med (1996) 11.76
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med (1998) 7.08
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med (1995) 6.97
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J (2009) 6.64
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet (2008) 5.01
Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med (2000) 4.13
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Molecular mobility and nucleocytoplasmic flux in hepatoma cells. J Cell Biol (1986) 3.48
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med (2001) 3.29
Inflammation in pulmonary arterial hypertension. Eur Respir J (2003) 3.18
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J (2010) 2.90
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet (2000) 2.82
Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med (1995) 2.76
Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest (2001) 2.59
BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet (2000) 2.51
Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med (1991) 2.45
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J (2009) 2.41
Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J (2004) 2.40
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J (2006) 2.39
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med (2000) 2.25
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Role of computed tomographic scanning of the thorax prior to bronchoscopy in the investigation of suspected lung cancer. Thorax (2000) 2.16
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J (1998) 2.14
Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax (2005) 2.03
Primary pulmonary hypertension and fenfluramine use. Br Heart J (1993) 2.02
Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J (2005) 1.98
Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med (2007) 1.86
Increased plasma serotonin in primary pulmonary hypertension. Am J Med (1995) 1.86
Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J (2009) 1.85
Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J (2006) 1.78
[Guidelines for the diagnosis and treatment of pulmonary hypertension]. Rev Mal Respir (2010) 1.74
Chronic thromboembolic pulmonary hypertension. Eur Respir J (2004) 1.74
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J (2004) 1.73
High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest (1999) 1.70
The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res (2006) 1.67
Semi-quantitative assessment of tricuspid regurgitation on contrast-enhanced multidetector CT. Clin Radiol (2004) 1.67
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med (2002) 1.65
Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. J Am Coll Cardiol (2001) 1.65
Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med (2015) 1.62
Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy (2004) 1.61
The use of combination therapy in pulmonary arterial hypertension: new developments. Eur Respir Rev (2009) 1.60
Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood (2000) 1.59
Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol (1997) 1.59
Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax (2003) 1.56
Thrombotic risk factors in pulmonary hypertension. Eur Respir J (2000) 1.54
Double lung transplantation in situs inversus with Kartagener's syndrome. Paris-Sud University Lung Transplant Group. J Thorac Cardiovasc Surg (1994) 1.53
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J (2007) 1.51
Association of pulmonary aspergilloma and allergic bronchopulmonary aspergillosis. Eur Respir Rev (2010) 1.51
Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med (2000) 1.51
Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J (1998) 1.51
Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med (1995) 1.46
Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. Eur Respir J (2008) 1.46
Pulmonary vascular disorders in portal hypertension. Eur Respir J (1998) 1.44
Prioritised research agenda for prevention and control of chronic respiratory diseases. Eur Respir J (2010) 1.41
Evidence of endogenous volatile organic compounds as biomarkers of diseases in alveolar breath. Ann Pharm Fr (2013) 1.40
[Adult asthma exacerbations in questions]. Rev Mal Respir (2010) 1.40
Reducing incidence of headache after lumbar puncture and intrathecal cytotoxics. Lancet (1999) 1.40
Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax (2004) 1.40
Fatal rupture of pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasis and severe PAH. Eur Respir Rev (2009) 1.39
[Lung transplantation]. Presse Med (1989) 1.39
Current differences in referral patterns for pulmonary endarterectomy in the UK. Eur Respir J (2008) 1.39
Management of severe pulmonary arterial hypertension. Eur Respir Rev (2010) 1.38
Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest (1994) 1.38
Pulmonary veno-occlusive disease. Eur Respir J (2009) 1.37
Pentamidine and pancreatitis. Ann Intern Med (1986) 1.34
Long term imatinib treatment in pulmonary arterial hypertension. Thorax (2006) 1.32
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J (2002) 1.31
Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax (2005) 1.29
Intraesophageal perfusion of acid increases the bronchomotor response to methacholine and to isocapnic hyperventilation in asthmatic subjects. Am Rev Respir Dis (1986) 1.26
Endocytosis and vesicle trafficking during tip growth of root hairs. Protoplasma (2005) 1.24
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy (2010) 1.24